CriticalClass III antiarrhythmics (Vaughan Williams)×Pharmacokinetic enhancer (booster) for antiretroviral therapy
Updated · Methodology
Mechanism
In the liver, CYP3A4 is the main enzyme that converts amiodarone into its active metabolite desethylamiodarone, and CYP3A4 inhibitors may slow this metabolism and raise amiodarone levels (amiodarone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Cobicistat is a strong CYP3A inhibitor used to boost atazanavir or darunavir, and it raises the levels of drugs that CYP3A metabolises (cobicistat SmPC, European Medicines Agency, EMA). The EU cobicistat SmPC places amiodarone among drugs that depend heavily on CYP3A for clearance and whose high levels are linked to serious or life-threatening reactions (cobicistat SmPC, EMA). Amiodarone has a long half-life of 20–100 days, and its interactions can persist for several months after it is stopped (amiodarone SmPC, AEMPS). The effect can also go the other way: amiodarone inhibits CYP3A4 and P-glycoprotein, and CYP3A inhibitors can reduce cobicistat clearance and raise its levels (amiodarone SmPC, AEMPS; cobicistat SmPC, EMA).
Symptoms
According to the cobicistat SmPC, high amiodarone levels are linked to serious or life-threatening adverse reactions (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA). Amiodarone can cause a slow heart rate, conduction disorders (sinoatrial and atrioventricular block), new or worsened arrhythmias, sometimes followed by cardiac arrest, and torsade de pointes (amiodarone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Its arrhythmias usually occur when QT-prolonging factors such as drug interactions or electrolyte disorders are present. Overdose has caused sinus bradycardia, heart block, ventricular tachycardia, circulatory failure and liver injury (amiodarone SmPC, AEMPS). A slow pulse or an arrhythmia causes dizziness, palpitations and fainting, while QT prolongation itself causes no symptoms and shows only on an electrocardiogram.
Management
The combination is contraindicated. The EU cobicistat SmPC names amiodarone among contraindicated drugs that depend heavily on CYP3A for clearance and whose high levels are linked to serious or life-threatening reactions (cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA). The same contraindication appears in the SmPCs of the combination tablets of cobicistat with darunavir, atazanavir and elvitegravir (SmPCs of these products, EMA). The amiodarone SmPC, for its part, recommends avoiding CYP3A4 inhibitors throughout amiodarone treatment, and the cobicistat SmPC describes cobicistat as a strong CYP3A inhibitor (amiodarone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS; cobicistat SmPC, EMA). The US cobicistat label is softer and recommends clinical monitoring with amiodarone (cobicistat label, US Food and Drug Administration, FDA). The US amiodarone label advises avoiding CYP450 inhibitors, including certain protease inhibitors (amiodarone FDA label). Amiodarone interactions can persist for several months after it is stopped (amiodarone SmPC, AEMPS, and FDA label), and no document says how long after amiodarone cobicistat can be started. Conditions for amiodarone itself: before starting, record an electrocardiogram (ECG) and measure potassium, correct low potassium and monitor the ECG throughout treatment (amiodarone SmPCs, AEMPS). Also correct low magnesium and calcium before starting (amiodarone FDA label). Stop amiodarone in second- or third-degree atrioventricular block, sinoatrial block or bifascicular block (amiodarone SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Amiodarona (nº registro 81291), sección 4.4 (2022)– AEMPS, CIMA, nº registro 81291, revisión 06/2022, sección 4.4
- AEMPS: Ficha técnica: Amiodarona, Trangorex 200 mg (nº registro 48048), secciones 4.3, 4.4 y 4.5 (2022)– AEMPS, CIMA, nº registro 48048, revisión 08/2022, secciones 4.3, 4.4 y 4.5
- FDA: Pacerone (amiodarone) prescribing information (2025)– FDA, DailyMed setid 4c4ec9b0-13a5-49a8-b57b-b3f64e4316a7 (Upsher-Smith Laboratories), version 27, revised 07/2025, sections 5.4 and 7 (Table 1)
- EMA: Ficha técnica: Cobicistat (EU/1/13/872), sección 4.5 (2026)– EMA, Tybost 150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 113872001, consultada 10/2026, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Atazanavir/cobicistat, Evotaz (EU/1/15/1025), sección 4.3 (2026)– EMA, Evotaz 300 mg/150 mg comprimidos (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.3 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, sección 4.3
- FDA: TYBOST (cobicistat) prescribing information (2026)– FDA, DailyMed setid 3784c35c-e87f-410c-900b-8fd6313c6010 (Gilead Sciences), versión 16 (SPL 10.02.2026, publicada 18.02.2026), secciones 4, 5.3, 7.1 y 7.3 (Table 7)
- EMA: Ficha técnica: Cobicistat, Tybost (EU/1/13/872), sección 4.3 (2026)– EMA, Tybost 150 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 113872001, consultada 20.10.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Elvitegravir/cobicistat/emtricitabina/tenofovir alafenamida, Genvoya (EU/1/15/1061), sección 4.3 (2026)– EMA, Genvoya 150 mg/150 mg/200 mg/10 mg comprimidos recubiertos con película (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151061001, consultada 20.10.2026, sin fecha de revisión en CIMA, secciones 4.3 y 4.5